Mayo Clinic Laboratory and pathology research roundup: October 12

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Featured Abstract
Effect of urate-elevating inosine on early Parkinson disease progression: The SURE-PD3 randomized clinical trial.
Urate elevation, despite associations with crystallopathic, cardiovascular, and metabolic disorders, has been pursued as a potential disease-modifying strategy for Parkinson disease (PD) based on convergent biological, epidemiological, and clinical data. Via PubMed
Published to PubMed This Week
- Effect of probiotics on incident ventilator-associated pneumonia in critically ill patients: A randomized clinical trial.
JAMA - Membranous nephropathy.
Nature Reviews - Diagnosis and classification of ileal pouch disorders: consensus guidelines from the international ileal pouch consortium.
Lancet Gastroenterol Hepatology - USP37 regulates DNA damage response through stabilizing and deubiquitinating BLM.
Nucleic Acids Research - SPOP mutation induces DNA methylation via stabilizing GLP/G9a.
Nature Communications - Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study.
Clinical Cancer Research - Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
Neuro Oncology - HLA antibody rates are not increased in a regional group of male COVID-19 convalescent plasma donors.
Clinical Infectious Disease - NSAID-induced colopathy.
Mayo Clinic Proceedings - Renal Neoplasia in Hyperparathyroidism-Jaw tumor syndrome.
Mayo Clinic Proceedings